Drug Profile
Farletuzumab ecteribulin - Eisai Inc
Alternative Names: Eribulin/farletuzumab antibody drug conjugate - Morphotek; Farletuzumab/eribulin ADC; MORAb-202Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Morphotek
- Developer Bristol-Myers Squibb; Eisai Inc
- Class 2 ring heterocyclic compounds; Antineoplastics; Cyclic ethers; Drug conjugates; Furans; Immunoconjugates; Ketones; Macrocyclic compounds; Monoclonal antibodies
- Mechanism of Action Apoptosis stimulants; Cadherin modulators; Receptor protein-tyrosine kinase modulators; Tubulin polymerisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Fallopian tube cancer; Non-small cell lung cancer; Ovarian cancer; Peritoneal cancer
- Phase I/II Solid tumours
Most Recent Events
- 11 Oct 2023 Pharmacodynamics data from a phase I Study 101 biomarker trial in Solid tumours presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2023 (AACR-NCI-EORTC-2023)
- 28 Jun 2023 Phase-II clinical trials in Non-small cell lung cancer (Late-stage disease, Metastatic disease, Second-line therapy or greater) in Australia, Chile, Spain (IV) (NCT05577715) (EudraCT2022-000131-23)
- 22 Feb 2023 Farletuzumab is still in phase I trials for Solid tumors in Japan (IV, Infusion) (Eisai pipeline, February 2023)